Our group will lead a new network of researchers interested in the delivery of antisense RNA therapeutics thanks to funding from COST (European Cooperation in Sience and Technology), which will begin in October 2018 and will last for 4 years.
The aim of this project is about the Antisense oligonucleotides (ASOs) that are a new class of drugs that, through very specific targeting, could correct genetic defects for rare inherited diseases, modulate autoimmune or neurodegenerative diseases or target tumors or viruses. However, only a few of such drugs are currently in the market and they have been less effective as expected. The main hurdle for their efficacy seems to be their deficient delivery to target tissues but, while translational research on ASO is surging, very little is known about the mechanisms by which ASOs are taken up by different tissues and specific cells.
COST Action CA1703 (DARTER) will act through 3 working groups and represents participants from COST countries and several international partners, including academics, industrial partners, as well as patient representatives and clinicians.
More information on Twitter: @AON_Delivery